COPENHAGEN, May 6 (Reuters) – Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported a first-quarter adjusted operating profit above expectations.
The Danish drugmaker is banking on demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies and investors demand proof that fast-rising volumes can offset a bruising obesity drug price war.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Comments